Related references
Note: Only part of the references are listed.Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
Christian J. Strasburger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Annamaria Colao et al.
PITUITARY (2016)
Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management
Mehdi Zeinalizadeh et al.
PITUITARY (2015)
Outcomes of Proton Therapy for Patients With Functional Pituitary Adenomas
Daniel A. Wattson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Stereotactic Radiosurgery for Acromegaly
Cheng-Chia Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
Roberto Salvatori et al.
PITUITARY (2014)
Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists
Trevor A. Howlett et al.
CLINICAL ENDOCRINOLOGY (2013)
Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide
Elisabeth Couture et al.
PITUITARY (2012)
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
Yasemin Tutuncu et al.
PITUITARY (2012)
Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment
Maria Matta et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy
Gherardo Mazziotti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly
Roberto Salvatori et al.
PITUITARY (2010)
Pituitary somatostatin receptor signaling
Anat Ben-Shlomo et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
The Utility of Oral Glucose Tolerance Testing for Diagnosis and Assessment of Treatment Outcomes in 166 Patients with Acromegaly
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide
N. Karavitaki et al.
CLINICAL ENDOCRINOLOGY (2008)
Somatostatin agonists for treatment of acromegaly
Anat Ben-Shlomo et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa
Jean Christophe Maiza et al.
CLINICAL ENDOCRINOLOGY (2007)
Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems
A. N. Paisley et al.
CLINICAL ENDOCRINOLOGY (2007)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial
A Colao et al.
CLINICAL ENDOCRINOLOGY (2006)
Effectiveness and tolerability of 3-year lanreotide Autogel® treatment in patients with acromegaly
P Caron et al.
CLINICAL ENDOCRINOLOGY (2006)
Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: An open-label, multicenter, non-comparative study
S Grottoli et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2005)
Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (Lanreotide Autogel)
B Gutt et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2005)
Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients
SW van Thiel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Efficacy of Sandostatin® LAR® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy
J Ayuk et al.
CLINICAL ENDOCRINOLOGY (2004)
Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR
O Alexopoulou et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results?
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly
J Ayuk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide
R Attanasio et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2001)
Share Paper
